The Role of LncRNAs in Uveal Melanoma

Paula Milán-Rois 1, Anan Quan 2, Frank J. Slack 2 and Álvaro Somoza 1,*

1 Instituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia),
Unidad Asociada al Centro Nacional de Biotecnología (CSIC), 28049 Madrid, Spain; paula.milan@imdea.org
2 Department of Pathology, Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School,
Boston, MA 02215, USA; aquan@bidmc.harvard.edu (A.Q.); fslack@bidmc.harvard.edu (F.J.S.)
* Correspondence: alvaro.somoza@imdea.org; Tel.: +34-91-299-8856

Simple Summary: Uveal melanoma is a rare cancer with a bad prognosis that needs new therapeutic and diagnostic approaches. In this regard, long non-coding RNAs (lncRNAs) play a pivotal role in cancer, among other diseases, and could be used as therapeutic targets of diagnostic markers. In this review, lncRNAs related to uveal melanoma are revealed to better understand their mechanism of action, and inspire the development of novel treatment and diagnostic approaches. In addition, the interaction of lncRNA with other non-coding RNAs (ncRNAs) is also discussed since it might be one of the most relevant mechanisms of action. The compiled information is helpful not only for uveal melanoma experts, but also for ncRNA cancer researchers.

Abstract: Uveal melanoma (UM) is an intraocular cancer tumor with high metastatic risk. It is considered a rare disease, but 90% of affected patients die within 15 years. Non-coding elements (ncRNAs) such as long non-coding RNAs (lncRNAs) have a crucial role in cellular homeostasis maintenance, taking part in many critical cellular pathways. Their deregulation, therefore, contributes to the induction of cancer and neurodegenerative and metabolic diseases. In cancer, lncRNAs are implicated in apoptosis evasion, proliferation, invasion, drug resistance, and other roles because they affect tumor suppressor genes and oncogenes. For these reasons, lncRNAs are promising targets in personalized medicine and can be used as biomarkers for diseases including UM.

Keywords: lncRNA; uveal melanoma; cancer; noncoding RNA; epigenetics; therapy; diagnosis

1. Introduction

For decades, a significant volume of research has been devoted to unraveling genes that encode proteins. However, in recent years, the non-coding genome has revolutionized biology, with more than 90% of the RNA in the human genome consisting of non-coding RNAs (ncRNAs). Furthermore, it has been demonstrated that ncRNAs have an essential role in cellular processes involving homeostasis and disease progression [1]. The complex network of interactions between multiple ncRNAs as well as between ncRNAs and coding RNAs highlights the ncRNAs’ fundamental role in regulating cellular processes, meaning that ncRNAs are taking part in several points of the cellular pathways controlling the expression of key genes. Therefore, dysregulation of ncRNA is directly related to neurodegenerative, developmental, metabolic diseases, or cancer.

The different types of ncRNAs can be classified by size into two main groups. Those with a length below 200 nucleotides (nts) are known as small ncRNAs such as the microRNAs (miRNAs), t-RNA-derived small RNAs (tsRNAs), and PIWI-interacting RNAs (piRNAs). In contrast, long non-coding RNAs (lncRNAs) include those above 200 nts in length including circular RNAs (circRNAs) and pseudogenes [1].

Although signaling pathways have long been characterized, lncRNAs are understudied, however, they have been shown to play an unexpected and essential role. Recently, lncRNAs have been discovered as critical players in regulatory networks. They interact...
with signaling molecules and regulators by making them more flexible or open to changes in the environment \[2\]. LncRNAs are involved in cellular pathways and mechanisms such as stem cell pluripotency, cell cycle regulation, metabolism, aging, cancer, and neurodegenerative and cardiovascular diseases \[3,4\]. They have a critical effect on the proliferation, invasion, or metastasis of tumors \[2\], which can be exploited to develop therapeutic agents or allow specific lncRNAs to be used as biomarkers \[5\].

However, substantial work is needed to understand the role of lncRNAs in homeostasis and disease progression. Indeed, it is rather challenging to elucidate the lncRNA roles and their implications in genetic regulation such as their effects in chromosome domain organization, nucleic acids and transcription factors subcellular localization, expression patterns, and genetic evolution or stability \[6\]. For example, lncRNAs are poorly conserved, which may seem contradictory with their relevant role in the cells. Furthermore, some lncRNAs can encode small functional peptides, suggesting that lncRNAs could also function as coding sequences \[7\]. Moreover, their flexibility and relatively large size have made it quite difficult to resolve their structures by classical methods such as X-ray crystallography, NMR spectroscopy, or electron microscopy. Moreover, lncRNAs play so many roles that it is complicated to assign roles to each annotated lncRNA \[8\]. LncRNA role assignation is done by loss of function approaches such as RNAi, ASOs, and CRISPR techniques. However, the inhibition by these processes is not as effective as in the case of mRNA, which complicates the elucidation of their roles \[6\]. Although these factors make it more complicated to unravel the biological function of lncRNAs, their roles are being studied individually and grouped according to their interaction with other molecules in cellular pathways \[4\].

In this review, we focus on long non-coding RNAs due to their crucial role in gene regulation through their interaction with proteins, DNA, and RNA. In particular, it is worth highlighting their interaction with a specific class of ncRNAs, microRNAs, as both have been implicated as genome master regulators \[6\].

Due to the variety of molecules with which lncRNAs can interact, their mechanism of action and functions are highly diverse (Figure 1). The biological processes in which lncRNA take part are included in Table 1 \[4,8\]. Their mechanism of action and function vary depending on the interaction molecule. Significant efforts have been dedicated to elucidate new lncRNA interactions and mechanisms. To achieve this goal, both experimental and computational techniques are essential to investigate new candidates and relate them to various diseases \[2–4,9\].

| Biological Process           | LncRNA                  | Citation     |
|-----------------------------|-------------------------|--------------|
| Transcription               | lncRNA NRON, lncRNA HSR1| \[10,11\]    |
| Splicing                    | lncRNA MALAT, lncRNA ASCO| \[12,13\]   |
| Translation                 | lncRNA HULC             | \[14\]       |
| RNA localization            | lncRNA XIST             | \[15\]       |
| RNA decay                   | lncRNA gadd7            | \[16\]       |
| RNA editing                 | lncRNA CTN              | \[17\]       |
| Epigenetic remodeling       | lncRNA HOTAIR           | \[18\]       |
| Genome integrity            | lncRNA NORAD, lncRNA CONCR| \[19,20\] |
| Structural functions        | lncRNA NEAT1, lncRNA FIRRE| \[21\]   |
| Cellular organelle functions| lncRNA RMRP, lncRNA SAMMSON| \[22,23\] |
Figure 1. The interaction of lncRNAs with different biomolecules tunes their biological activity. LncRNAs can interact with proteins, DNA, or RNA, acting as (A) scaffolds of proteins, (B) decoys, preventing protein–oligonucleotide complex formation, (C) guides for (i) proteins or (ii) oligonucleotides, (D) enhancers, promoting transcription, (E) miRNAs sponges, or (F) mRNA inhibitors, blocking mRNA function due to (i) mRNA degradation, (ii) blocking translation, or (iii) competing for binding sites. Created with BioRender.com.

LncRNA–protein interactions are involved in transcription, post-transcription, splicing, molecular scaffolds, or decoys. For example, these interactions can allow for protein-DNA recognition to induce or repress transcription, the recruitment of chromatin-modifying enzymes, or the cooperation with splicing factors (involved in the regulation of alternative splicing). The current methods to detect these interactions are electrophoresis, RNA-pull down assay, fluorescence in-situ hybridization (FISH) colocalization, oligonucleotide-targeted RNase H assay, and high throughput transcriptomics or proteomics [2,24].

LncRNA interactions with DNA have been implicated in transcription (e.g., participating in enhancers or chromatin looping processes), DNA repair capacity, and nuclear body formation and function. The techniques to elucidate these mechanisms are based on chromatin isolation by RNA purification (ChIRP), capture hybridization analysis of RNA targets (CHART), RNA antisense purification (RAP), chromatin oligo affinity precipitation (ChOP) [24–26], and recently computer tools such as GRIDseq, Triplexator, or LongTarget [27].

LncRNAs can also interact with ncRNAs such as microRNAs, which leads to their inhibition or activation. Additionally, they can interact with mRNAs, affecting their alternative splicing or stability, inhibiting translation, or even competing for binding sites [25]. Some techniques to study these interactions include selective 2′-hydroxyl acylation analyzed by primer extension sequencing (SHAPE-Seq), RNA antisense purification (RAP), selective
2′-hydroxyl acylation analyzed by primer extension mutational profiling (SHAPE-Map), dimethyl sulfate sequencing (DMS-Seq), fragmentation sequencing (FRAG-seq), parallel analysis of RNA structure (PARS), parallel analysis of RNA structure with temperature elevation (PARTE) or in vivo click selective 2′-hydroxyl acylation analyzed by primer extension (icSHAPE) [25].

LncRNAs can be classified according to their cis or trans function or position relative to coding genes [2,28], the latter of which is the preferred method [2,29]. This classification categorizes lncRNA into the following types:

- **Intergenic**, the lncRNAs transcribed from DNA strands between protein-coding genes. These lncRNAs act as master regulators of transcription and posttranscriptional and translation processes [30].
- **Intronic**, the lncRNAs transcribed from introns in the same orientation as the mRNA of protein-coding genes. Many of these lncRNAs are implicated in alternative splicing [31].
- **Overlapping**, the lncRNAs transcribed from overlapping mRNA of protein-coding genes. Many overlapping lncRNAs have implications in splicing, tissue specificity, and aging [32].
- **Antisense**, the lncRNAs transcribed from the opposite strand (antisense) of protein-coding genes. These lncRNAs can interfere with transcription or mRNA stability [33].

Some members of all of these types are related to diseases; for example, there are intergenic lncRNAs such as Doublesex And Mab-3 Related Transcription Factor 2 (DMRT2), involved in obesity progression, and linc1992, involved in immune disorders [30]; intronic lncRNAs such as Prostate Cancer Associated Transcript 19 (PCAT19) associated with poor prostate cancer prognosis [34]; overlapping lncRNA Sex determining Region Y-box 2 (SOX2) promotes Ewing’s sarcoma proliferation [35]; antisense lncRNAs such as HOXA-AS2 promotes many human cancers [36] or lncRNA β-secretase 1 antisense (BACE1-AS) related to Alzheimer’s disease [8]. lncRNAs associations with multiple diseases indicate that they might be considered as targets for therapeutic or diagnostic system development [2,37].

LncRNAs are involved in many of the hallmarks of cancer as described by Hanahan and Weinberg [38] such as proliferation, motility, immortality, angiogenesis, inflammation, drug resistance, genomic stability, and cell viability. In fact, recent studies of transcriptome profiles generated via next-generation sequencing have found many lncRNAs to be mutated or abnormally expressed in tumors [39]. In this sense, lncRNAs could drive cancer phenotypes, acting as tumor suppressors, oncogenes, or both [40,41]. It is necessary to correlate the activity of each lncRNA with key cancer players to determine which lncRNA belongs in which category [42,43]. The cancer lncRNA list is continuously growing and compiled in databases such as Lnc2Cancer or the Cancer LncRNA Census [8,44,45].

In healthy cells, tumor suppressor genes are activated when cells detect oncogenic stress to maintain homeostasis. Interestingly, several lncRNAs are involved in regulating those genes [42], leading mainly to reducing tumor cell growth, proliferation, invasion, and metastasis. However, when these genes or lncRNAs are downregulated, cancer develops [44]. Tumor suppressor lncRNAs (Figure 2) can be used as therapeutic agents because they can interact with oncogenes, directly or indirectly, reducing their expression levels and, therefore, tumor progression [42].
In this sense, lncRNAs could drive cancer phenotypes, acting as tumor suppressors, oncogenes, or both [40,41]. It is necessary to correlate the activity of each lncRNA with key cancer players to determine which lncRNA belongs in which category [42,43]. The cancer lncRNA list is continuously growing and compiled in databases such as Lnc2Cancer or the Cancer LncRNA Census [8,44,45]

In healthy cells, tumor suppressor genes are activated when cells detect oncogenic stress to maintain homeostasis. Interestingly, several lncRNAs are involved in regulating those genes [42], leading mainly to reducing tumor cell growth, proliferation, invasion, and metastasis. However, when these genes or lncRNAs are downregulated, cancer develops [44]. Tumor suppressor lncRNAs (Figure 2) can be used as therapeutic agents because they can interact with oncogenes, directly or indirectly, reducing their expression levels and, therefore, tumor progression [42].

Figure 2. Scheme of tumor suppressor lncRNA pathways in uveal melanoma. (A) lncRNA PAUPAR, (B) lncRNA NUMB, (C) lncRNA CAN1/CASC15-NT1, (D) lncRNA ZNNT1, (E) lncRNA SNGH7, and (F) LncRNA GAS5. Created with BioRender.com, accessed on 26 October 2020.

In addition, there are homeostatic pathways involved in cellular proliferation, for example, gastric epithelial maintenance. When these processes are deregulated, cancer appears. Oncogenic lncRNAs (Figure 3) play pivotal roles in oncogenic transformation because they are involved in cellular pathways that promote carcinogenesis [42,45]. Oncogenic lncRNAs are usually upregulated in cancer and promote cell growth, angiogenesis, migration, invasion, apoptosis evasion, and chemoresistance [46]. Oncogenic lncRNAs are promising therapeutic targets because they can be inhibited by siRNAs, antisense oligonucleotides (ASOs), or via Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) techniques, leading to tumorigenesis reduction [47]. In addition, they can be used as biomarkers because high levels of these lncRNAs can be related to tumor surveillance [42].
In addition, there are homeostatic pathways involved in cellular proliferation, for example, gastric epithelial maintenance. When these processes are deregulated, cancer appears. Oncogenic lncRNAs (Figure 3) play pivotal roles in oncogenic transformation because they are involved in cellular pathways that promote carcinogenesis [42,45]. Oncogenic lncRNAs are usually upregulated in cancer and promote cell growth, angiogenesis, migration, invasion, apoptosis evasion, and chemoresistance [46]. Oncogenic lncRNAs are promising therapeutic targets because they can be inhibited by siRNAs, antisense oligonucleotides (ASOs), or via Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) techniques, leading to tumorigenesis reduction [47]. In addition, they can be used as biomarkers because high levels of these lncRNAs can be related to tumor surveillance [42].

![Figure 3. Scheme of oncogenic lncRNA pathways in UM. (A) LncRNA MALAT1, (B) LncRNA PVT, (C) LncRNA RHPN1-AS1, (D) LncRNA HOXA11-AS, (E) LncRNA FTH1P3, (F) LncRNA P2RX7-V3, and (G) LncRNA LOC100132707. Created with BioRender.com.](image-url)
LncRNAs have been found to be involved in many types of cancers such as prostate, breast, brain, lung, liver, pancreatic, colorectal, renal, ovarian, and gastric cancer [2,48]. However, lncRNA responses to cancer treatments (e.g., chemotherapy or immunotherapy) or their relationship with the tumor microenvironment are understudied [8].

In this review, we have described the roles of these ncRNAs in a rare type of cancer of the eye, uveal melanoma (UM).

2. Uveal Melanoma

Uveal melanoma (UM) is a type of intraocular cancer tumor. It is considered a rare disease due to its low prevalence, making up just 3–5% of all cancers within the U.S. population [49]. It principally appears in the choroid, iris, and ciliary body. UM has a high metastatic risk and a poor prognosis as 90% of patients die within 15 years of diagnosis [50].

In most (83%) cases, UM is caused by mutations in the alpha subunit of the heterotrimeric G gene (GNAQ) or its parologue GNA11. In addition, UM usually presents other genetic alterations such as the loss in chromosome 3 and gain in chromosome 8q. The prognosis of this disease is worrying since patients frequently undergo liver metastasis and succumb within 2–6 months [51]. In metastatic UM, there are also mutations in breast cancer gene (BRCA) associated protein 1 gene (BAP1) on chromosome 3, which results in aggressive cancer [52].

Besides the genetic causes, there are also critical epigenetic alterations in the UM carcinogenesis process (e.g., ncRNA abnormalities, DNA methylation, and histone modifications) [53–55] that are also understudied. Regarding ncRNAs, it is described that microRNAs and lncRNA dysregulated levels affect the tumorigenesis process and the final prognosis. LncRNAs affect several points of the UM pathways, notably at the MAPK/ERK or PI3K/AKT pathways [56]. These aberrations should be taken into account with the alterations described by Thornton et al. to classify the patients in proper treatment groups [55].

Enucleation, radiotherapy, or laser therapy are the current standard therapeutic options for primary resectable UM tumors. However, for unresectable and/or metastatic tumors, systemic chemotherapy is the main treatment. Since UM cells are drug-resistant in primary and metastatic tumors, chemotherapy is usually applied as a combination of different drugs such as dacarbazine, temozolomide, gemcitabine, or treosulfan [57]. Nonetheless, in a meta-analysis of current treatments (e.g., chemotherapy or radiotherapy) for metastatic UM, all treatments positively affected overall survival or reduced the metastatic risk [58–60]. However, there are promising novel treatments in clinical trials that combine chemotherapy agents with photodynamic therapy, immunotherapy, or targeted therapy for metastatic UM [61]. Despite this progress, the aberrations compilation indicates UM is a disease with a poor prognosis and low survival rates. For these reasons, new treatments and diagnosis methods are needed not only to focus on genetic, but also epigenetic drivers.

3. LncRNAs in Uveal Melanoma

As above-mentioned, dysregulated lncRNAs are implicated in many cancers including UM. In the following sections, their role in UM is discussed, and their main mechanisms and roles are summarized in Table 2 [62].
Table 2. LncRNAs implicated in UM progression.

| LncRNA Name          | Mechanism                                                                 | Role          | Reference     |
|----------------------|---------------------------------------------------------------------------|---------------|---------------|
| lncRNA CASC15        | Switches tumor phenotype through MITF and/or SOX10                        | Oncogenic     | [56]          |
| lncRNA P2RX7-V3      | Affects PI3K/AKT pathway                                                  | Oncogenic     | [63]          |
| lncRNA MALAT1        | Suppresses miR-608. Promotes miR-140 expression and suppresses Slug and ADAM10 expression. | Oncogenic     | [64,65]       |
| lncRNA PVT1          | Regulates the expression of EZH2 and blocks miR-17-3p                     | Oncogenic     | [66,67]       |
| lncRNA RHPN1-AS1     | Participates in TGF-β pathway                                             | Oncogenic     | [68]          |
| lncRNA HOXA11-AS     | Suppresses p21 and acts as a sponge of miRNA-124                          | Oncogenic     | [69]          |
| lncRNA FTH1P3        | Suppresses miRNA 224-5p expression and promotes the expression of Rac1 and Fizzled 5 | Oncogenic     | [70]          |
| lncRNA LINC00518     | Participates in the metastatic process                                    | Oncogenic     | [71]          |
| lncRNA LOC100132707  | Promotes migration via JAK2                                              | Oncogenic     | [72]          |
| lncRNA PAUPAR        | Modulates HES1 expression                                                 | Tumor suppressor | [73]        |
| lncRNA NUMB          | Restores the expression of HIC1 (Hypermethylated in cancer 1)            | Tumor suppressor | [74]        |
| lncRNA CANT1         | Modulates JPX or FTX by methylation at their promoters                   | Tumor suppressor | [75]        |
| lncRNA ZNNT1         | Promotes autophagy                                                        | Tumor suppressor | [76]        |
| lncRNA SNHG7         | Regulates EZH2 pathway                                                    | Tumor suppressor | [77]        |
| lncRNA GAS5          | Induces PTEN expression                                                   | Tumor suppressor | [78]        |

Many of the lncRNAs compiled in this article are those broadly studied in other cancers. Nevertheless, less lncRNA research has been conducted in UM, so it needs further investigation in the UM field. In some cases, the mechanism involved in UM is not the same as the one previously studied, and oncogenic lncRNAs act in UM as tumor suppressors or vice versa.

3.1. Tumor Suppressor LncRNAs in Uveal Melanoma

Tumor suppressor lncRNAs can act directly on effector molecules or act as regulator elements, for instance, controlling transcription. Depending on the mechanism of action, they can activate tumor suppressor pathways (Figure 2B–D) or block the tumorigenesis process (Figure 2A,E).

Some examples of tumor suppressors in UM are presented below (Figure 2).

LncRNA Pax6 Upstream Antisense RNA (PAUPAR) is a lncRNA that is transcribed upstream of the Pax6 transcription factor. It was first identified in neuroblastoma modulating Paired Box 6 (PAX6) activity [79]. This protein controls progenitor cell potency and proliferation, specification, and spatial patterning in neural cells [80,81]. LncRNA PAUPAR is downregulated in UM, blocking cell migration and tumor formation. Its downstream target is Hairy and Enhancer of Split 1 (HES1), a critical player in the NOTCH signaling pathway, controlling the survival or apoptosis of melanocytes [73]. Highly expressed in UM, HES1 promotes proliferation and invasion [82]. Increased levels of lncRNA PAUPAR alters the expression of HES1 acting on Histone H3 lysine K4 (H3K4) methylation, related to the transcription of HES1. In other words, LncRNA PAUPAR reduces HES1 transcription, which reduces proliferation and invasion [73].

Another notable lncRNA is NUMB. It is encoded upstream of the NUMB protein gene, which can reduce tumor formation and prevent invasion in UM cell lines. Hypermethylated in cancer 1 (HIC1) regulates lncRNA NUMB in uveal melanoma. HIC1 promotes lncRNA expression, acting as a transcriptional activator [74]. LncRNA NUMB acts as a tumor suppressor by inhibiting cell proliferation and invasion. However it is downregulated in UM [74,83].
LncRNA Calcium Activated Nucleotidase 1 (CANT1), also known as CASC15-NT1, is a typical cancer-associated lncRNA. This downregulated tumor suppressor lncRNA is an isoform of lncRNA Cancer Susceptibility 15 (CASC15) implicated in UM. [75,84]. LncRNA CANT1 controls the expression of the lncRNA X-inactive specific transcript (XIST) (XIST is implied in chromosome X gene repression) [85]. Moreover, lncRNA CANT1 regulates JPX or five prime to Xist (FTX) transcription factors through their promoter methylation by H3K4. This pathway contributes to tumorigenesis in UM [75].

The lncRNA ZNF706 Neighboring Transcript 1 (ZNNT1) promotes autophagy in UM through mTOR inhibition but is downregulated in tumors. LncRNA ZNNT1 controls the expression of autophagy-related 12 (ATG12) and modulates the ATG12-ATG15 conjunction. This mechanism produces cell death and tumorigenesis suppression. Furthermore, the lncRNA could act in proteosome inhibitor-mediated apoptosis [76].

It is worth highlighting that several lncRNAs play dual roles such as the lncRNA Small Nucleolar RNA Host Gene 7 (SNHG7), which has tumor suppressor or oncogenic activity depending on the kind of cancer. For instance, it has oncogenic properties in several cancers such as pancreatic, bladder, colorectal, gastric, and breast cancer [77,86–90]. Whereas, in UM, lncRNA SNHG7 can inhibit malignant transformation due to its effect on the Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) protein, which regulates cell proliferation, the cell cycle, and apoptosis. Specifically, the lncRNA SNHG7 can inhibit EZH2, reducing UM progression [77]. Similarly, it has been described that in lung cancer, this lncRNA can also work as a sponge of the oncogenic miR-181 (which promotes cell proliferation and migration), reducing the activity of miR-181 and, therefore, the tumoral progression [91].

The lncRNA Growth Arrest Specific 5 (GAS5) is downregulated in UM, and is usually associated with a bad prognosis. This lncRNA blocks the oncogenic miR-21, which leads to epithelial-mesenchymal transition (EMT) via Phosphatase and tensin homolog (PTEN) activation. Therefore, the final result of lncRNA GAS5 downregulation is invasion [78].

3.2. Oncogenic LncRNAs in Uveal Melanoma

Some examples of oncogenic lncRNAs in UM are presented below (Figure 3). As in the tumor suppressor case, oncogenic lncRNA could activate oncogenic molecules or inhibit tumor suppressor elements.

A classic lncRNA with an oncogenic role is lncRNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) (Figure 3). It is also known as nuclear-enriched abundant transcript 2 (NEAT2), and is upregulated in different kinds of cancer such as lung, glioma, bladder, colorectal, gastric, and breast cancer [77,86–90]. Whereas, in UM, lncRNA SNHG7 can inhibit malignant transformation due to its effect on the Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) protein, which regulates cell proliferation, the cell cycle, and apoptosis. Specifically, the lncRNA SNHG7 can inhibit EZH2, reducing UM progression [77]. Similarly, it has been described that in lung cancer, this lncRNA can also work as a sponge of the oncogenic miR-181 (which promotes cell proliferation and migration), reducing the activity of miR-181 and, therefore, the tumoral progression [91].

The lncRNA Growth Arrest Specific 5 (GAS5) is downregulated in UM, and is usually associated with a bad prognosis. This lncRNA blocks the oncogenic miR-21, which leads to epithelial-mesenchymal transition (EMT) via Phosphatase and tensin homolog (PTEN) activation. Therefore, the final result of lncRNA GAS5 downregulation is invasion [78].
Another oncogenic lncRNA is IncRNA Rhophilin Rho GTPase binding protein 1 antisense RNA 1 (RHPN1-AS1), which is overexpressed in UM compared to healthy tissues. This lncRNA is associated with angiogenesis, cell adhesion, and extracellular matrix organization. Therefore, IncRNA RHPN1-AS is implicated in the epithelial-mesenchymal transition (EMT) through the Transforming growth factor beta (TGF-β) signaling pathway interaction [68]. In other cancers, it acts with/against miRNAs to promote cancer such as in cervical cancer through the miR-299-3p/Fibroblast Growth Factor 2 (FGF2) axis [99], in glioma targeting miR-652-5p/Regenerating islet-derived protein 3-alpha (REG3A) [100], in breast cancer sponging miR-6884-5p [101], or sponging miR-7-5p in colorectal cancer [68], but none of these relations have been studied in UM yet.

The lncRNA Homeobox A11 (HOXA11), also known as NCRNA00076, belongs to the Homeobox A (HOXA) cluster with lncRNA Homeobox A10 antisense (HOXA10AS) and HOXA Distal Transcript Antisense RNA (HOTTIP), all of which are involved in cancer proliferation, invasion, migration, and chemoresistance [102,103]. LncRNA HOXA11AS is upregulated in many cancers such as non-small cell lung cancers, osteosarcoma, glioma, hepatocellular carcinoma, gastric, breast, cervical cancer, and UM [104]. LncRNA HOXA11 acts as a sponge for the tumor suppressor miR-124 in breast cancer and, through interaction with EZH2, inhibits protein p21 (p21) [105]. In UM, the high concentration of lncRNA HOXA11AS leads to proliferation and invasion. This effect could be reversed with miR-124 mimic transfection [69].

The high levels of lncRNA Ferritin Heavy Chain 1 Pseudogene 3 (FTH1P3) in UM correlate with proliferation, cell cycle, and migration. It is dysregulated in other cancers such as lung, cervical, glioma, esophageal carcinoma, and breast cancer [106–110]. It is suggested that lncRNA FTH1P3 decreases miR-224-5p expression and enhances Fizzled 5 and Ras-related C3 botulinum toxin substrate 1 (Rac1) expression, promoting cell cycle progression and migration [70].

Purinergic Receptor P2X 7 (P2RX7), a ligand-gated ion channel receptor, is overexpressed in several cancers and is expressed differently in many tissues. This receptor participates in tumor growth, differentiation, metabolism, migration invasion, and cell death, so the P2RX7 overexpression is related to poor prognosis in patients [111]. It has been reported that the lncRNA P2RX7-V3 variant acts as an oncogene because of the positive correlation with the P2RX7 receptor. Although the action mechanism is not clear, the lncRNA P2RX7-V3 variant is upregulated, and is involved in the tumor maintenance of UM cell lines. Moreover, the analysis of the P2RX7-V3 lncRNA targets demonstrates that the lncRNA participates in the Phosphatidylinositol 3-kinase (PI3K)-Protein kinase B (AKT) pathway promoting tumorigenesis [63].

The lncRNA LINCO00518 is overexpressed in the cytoplasm of UM cells, but it has not been detected in extracellular fluids. Therefore, it is currently not useful as a biomarker. It is proposed that lncRNA LINCO00518 could act as a miRNA sponge modulating the metastatic process; however, the cellular pathway has not been well established yet [71].

The lncRNA LOC100132707 is overexpressed in metastatic UM, and is correlated with the Janus kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which are signal transducers and activators of transcription. The activation of this signaling leads to migration and invasion [72].

4. LncRNAs as Therapeutic Agents

Selecting a proper lncRNA for therapeutic use requires tissues to present different expression profiles between tumors and healthy cells. It is essential that the differential levels are due to aberrant cancer expression to target the tumor exclusively. If the therapy is effective (upregulating tumor suppressor lncRNAs or downregulating oncogenic ones), the modulation of lncRNA expression should induce cell death, or reduction in tumor size or motility [112].

Several features make lncRNAs ideal molecules for cancer treatment: (a) lncRNA concentration is lower than mRNAs, besides lncRNA have a fast turnover, meaning they
react fast with the targets; (b) lncRNAs are specific for certain cells/tissues specific, making them ideal for the selection of cell subpopulations and develop selective therapeutics; (c) LncRNAs can control chromatin modifications; therefore, targeting LncRNAs could be exploited to modulate the epigenetics of the cells; (d) LncRNAs could modulate chromatin function, regulate the assembly of nuclear bodies, or affect stability and translation of mRNA; (e) LncRNAs have many binding sites, thus, blocking different lncRNAs domains could lead to more efficient therapy because of their effect in multiple proteins of dysregulated pathways; and (f) targeting LncRNAs provides simultaneous effects in several pathways, so there are fewer chances to develop tumor resistance [8,112–115].

There are several strategies to modulate upregulated lncRNA expression depending on their subcellular localization and mechanism of action [31,41,50,116–118]:

- Inhibit oncogenic lncRNA expression using specific siRNAs, antisense oligonucleotides (ASOs), gapmers, ribozymes, and Dnazymes, synthetic lncRNA mimics, or CRISPR systems.
- Block the interaction between lncRNAs and their target molecules (e.g., regulatory factors or promoters) or affect the lncRNA secondary structure with aptamers or small synthetic molecules.

In the case of downregulated lncRNAs, therapies are focused on increasing tumor suppressor lncRNA levels to restore the normal expression levels [119].

Although new therapies against lncRNAs have been developed, there are many challenges in delivering oligonucleotides because of their natural degradation, immune system activation, and difficulties in targeting cancer cells and their organelles [120]. Various delivery systems have been developed to overcome these limitations such as liposomes, micelles, dendrimers, inorganic particles, carbon nanotubes, nanoparticles, viral nanocarriers, polymeric or peptide nanoparticles, metallic nanoparticles, and others [116–118,121–126]. Through the use of delivery systems, side effects can be reduced due to accurately targeting the tumoral cells (e.g., using polycation gene vectors for delivering lncRNA Maternally Expressed 3 (MEG3) in hepatocellular carcinoma [127], or gold nanoparticles with Tyrosine Aminotransferase (TAT) peptide to deliver specifically into lung cancer cells ASOs against lncRNA MALAT) [128]. Notably, by using nanoparticle-based approaches, stimuli-sensitive systems can be implemented to improve control over the release. One example of this is the delivery of siRNAs against the lncRNA Differentiation Antagonizing Non-Protein Coding RNA (DANCR) with pH-sensitive amino lipid, polyethylene glycol, and peptide formulations. These formulations are being used to treat triple-negative resistant breast cancer models [129]. Moreover, exosomes are gaining relevance in this field because of their low immunogenicity and good biocompatibility and stability. However, exosomes are not as tunable as other nanoformulations. For this reason, they are used to hybridize with other nanoparticles (e.g., liposome-exosome nanoformulations) to deliver CRISPR-Cas 9 [130].

Regarding UM, therapies based on lncRNA could target tumor melanocytes by taking advantage of lncRNA tissue specificity and delivery systems. Selecting the proper oncogenic lncRNA and delivering therapies against it would reduce tumor size, avoiding side effects. Moreover, these therapies could reach metastatic cells such as liver metastasis (e.g., targeting lncRNA Receptor Tyrosine Kinase Like Orphan Receptor 1 antisense 1 (ROR1-AS1) or lncRNA Homeobox D antisense (HOXD-AS1)) [131,132], which is the main cause of death in UM patients.

5. LncRNAs as Diagnostic Agents

It is well known that early diagnosis is fundamental to improve the survival of cancer patients. In addition, it is also necessary to monitor cancer progression. In this regard, X-ray, magnetic resonance imaging, histopathology, molecular pathology, circulating tumor cell detection, and tomography are the most common diagnostic methods in the clinic, but most of them are expensive and invasive techniques; therefore, new non-invasive, real-time, and reproducible diagnostics are desired [133,134].
UM used to be diagnosed by enhanced depth imaging optical coherence tomography (EDI-OCT) and fluorescein or indocyanine green angiography (FFA or ICG) [50], however, metastatic UM has a challenging detection because of the early dissemination and micrometastasis, principally in the liver [135]. Thus, UM is usually detected after the tumor has grown significantly, affecting liver function [136]. Cytogenetic diagnosis is recommended, but these kinds of tests are invasive and conducted after tumor biopsies [135]. For liver metastasis, the standard techniques are abdominal ultrasound and liver biochemical function test. In general, blood biomarkers are the best option to diagnose, establish a prognosis, and predict therapeutic response in metastatic and non-metastatic UM [135].

Many lncRNAs are cancer-specific or aberrantly expressed in some cancer tissues, making them exploitable as biomarkers. LncRNAs could indicate the presence or absence of cancer and even the disease progression. Furthermore, lncRNAs are stable in blood, saliva, and urine, and they are detected in circulating extracellular vesicles [137]. Therefore, they can be excellent markers in non-invasive tests for personal and precision oncology [50,138–140].

Interestingly, as stated before, lncRNA expression could be correlated to the tumor stage and, therefore, with cancer prognosis or tumor recurrence. This correlation is explained because different types of tumors at various stages of progression present distinct levels of lncRNA depending on the cellular pathways affected [133].

Some lncRNAs are already being used as biomarkers in the clinic such as the lncRNA Prostate cancer antigen 3 (PCA3) approved by the FDA as a prostate cancer biomarker, with a sensitivity of 58–82% and a 56–76% specificity [141]. In UM, several lncRNAs are already used for diagnosis in basic research (Table 3) [133].

| LncRNA            | Expression Level | Source                      | Association                                                                 | Reference        |
|-------------------|------------------|-----------------------------|----------------------------------------------------------------------------|------------------|
| lncRNA PVT1       | Up               | Tumor, gastric juice, serum | Poor overall survival                                                       | [94]             |
| lncRNA HOXA11AS   | Up               | Tumor                       | Poor overall survival                                                       | [104]            |
| lncRNA SNHG7      | Down             | Tumor                       | Higher tumor-node-metastasis stage (TNM) and poor histological type         | [77,79,97]       |
| lncRNA MALAT1     | Up               | Tumor, urine, serum         | Melanoma progression and metastasis                                         | [133]            |
| lncRNA CASC15     | Up               | Tumor                       | Cancer recurrence                                                           | [133]            |

The current lncRNA detection methods include northern blot, qRT-PCR, RNA-seq, and microarrays. Although it is possible to detect lncRNA with these techniques, not many lncRNA biomarkers are approved for routine diagnoses in humans. The reason for this is the lack of extensive cohort studies and inconsistent acquisition and analysis methods. Furthermore, there is no agreement on suitable sample tissue, RNA isolation method, sequencing, analysis, or biostatistics techniques; all these steps should be standardized for proper clinical translation.

Nowadays, some blood biomarkers are used in UM such as tumor-associated antigen (MIA), osteopontin, and S-100β, among other hepatic markers. These biomarkers are present at high concentrations in UM patients with liver metastasis [136]. However, any lncRNA biomarker currently used in the clinic has an enormous potential to be applied for UM detection and monitoring, because they would be found in blood and are cancer-specific, sensitive, and the technique is cost-effective, rapid, and non-invasive [135].

In summary, using two or more lncRNAs in combination with currently used biomarkers significantly increases the specificity and sensitivity in cancer diagnosis [94,95].
6. LncRNA-microRNA Interactions Related to Uveal Melanoma

As previously mentioned, the interaction between different ncRNAs permits regulatory subcategories in the genome, which means that ncRNA levels depend on other ncRNAs. In particular, the relationship between lncRNAs and microRNAs is very important due to the crucial roles in both the homeostasis and disease processes [5].

Despite the large number of lncRNA–microRNA interactions in nature, very few have been described in UM. This absence is related not only to the lack of research in UM, as it is a rare disease, but also because of the novelty of this research field. Recently, a database called VECTOR (uVeal mElanoma Correlation NeTwORk) has been published to predict RNA interactions in UM [142], which will be very helpful in this field.

The main contributions in this area are discussed below.

LncRNA PVT1 is an oncogenic lncRNA related to metastasis risk. This lncRNA binds miR-17-3p, reducing its expression levels. Moreover, miR-17-3p often downregulates MDM2 expression, a protein that inhibits p53. In UM, the lncRNA PVT1 is highly expressed, and therefore miR-17-3p is inhibited, leading to MDM2 upregulation and p53 inhibition [67]. This relationship has been described in other cancers such as gastric cancer or neuroblastoma [138,143]. The study of this regulatory pathway in which lncRNAs and microRNAs are involved might allow for the design of promising therapies to reduce the expression of lncRNA PVT1 or increase the levels of miR-17-3p to achieve cancer regression. Moreover, the presence of the high levels of lncRNA PVT1 could be used as a biomarker to detect UM [67].

Another well-known oncogenic lncRNA is MALAT1. This lncRNA is also implicated in metastasis and correlates with advanced tumor stages and poor survival in several cancers such as lung adenocarcinoma, breast cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, and others [144]. LncRNA MALAT1 regulates miR-608, a tumor suppressor that inhibits HOXC4, a homeobox family’s transcription factor [139], and AKT2, an oncogene kinase [140], leading to apoptosis. In UM, MALAT1 is overexpressed, which reduces the expression of miR-608, leading to an increase of HOXC4. Thus, these processes together enhance UM cell proliferation and invasion [65].

LncRNA HOXA11AS is an oncogenic lncRNA involved in UM progression, and its overexpression is related to cell growth, migration, and apoptosis evasion. This lncRNA can bind EZH2 [69], a polycomb family member with a key role in the cell cycle, cell death, and cell lineage determination [145]. Additionally, LncRNA HOXA11AS works as a miR-124 sponge, which controls EZH2 expression levels and causes apoptosis and/or autophagy [146]. Therefore, low miR-124, mediated by HOXA11AS, releases EZH2, inhibiting the tumor suppressor p21. Interestingly, it has been shown that by increasing miR-124 levels, proliferation and invasion were reduced in UM cells [69], highlighting the potential use of lncRNAs as therapeutic targets.

7. Conclusions

LncRNA are fascinating molecules involved in UM progression. Regarding their biological implications, lncRNA can interact with diverse types of molecules. For instance, they can interact with proteins acting as protein scaffolds, oligonucleotide decoys, or guides; also with DNA, acting as guides or enhancers; or with other RNA structures as miRNA sponges or mRNAs inhibitors.

Since LncRNAs are implicated in tumor formation and progression in uveal melanoma, they can be excellent biomarker candidates for non-invasive diagnostic techniques. In this scenario, oncogenic LncRNAs such as PVT1, CASC15, or MALAT1 are perfect candidates to develop diagnostic methods because they are more abundant in UM tumors or even patient serum. Furthermore, oncogenic LncRNAs are also remarkable targets to inhibit tumors, increase drug sensibility, and prevent chemoresistance or future relapses. In particular, tumor suppressor LncRNAs such as LncRNA PAUPAR or NUMB can be used as therapeutic molecules to reduce tumor progression in UM. It is worth mentioning that these therapeutic
approaches face some challenges associated with drug delivery in vivo (e.g., stability, internalization), which might be overcome through the use of modern nanocarriers.

Finally, it is clear that a better understanding the lncRNAs’ roles will provide us with new tools to detect and treat UM, which are needed to tackle this terrible disease. In this regard, this review could be very valuable to better understand the implications of LncRNAs in UM and promote this area of research.

Author Contributions: Writing—original draft preparation, P.M.-R.; Writing—review and editing, P.M.-R., A.S., A.Q., and F.J.S.; Supervision, A.Š. and F.J.S.; Project administration, A.Š.; Funding acquisition, A.Š. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by ‘Severo Ochoa’ Program for Centers of Excellence in R&D (MINECO) grant numbers SEV-2016-0686-17-3, SAF2017-87305-R, CEX2020-001039-S, BES-2017-082521, the Spanish Ministry of Economy and Competitiveness (PID2020-119352RB-I00), Comunidad de Madrid (IND2017/IND-7809; S2017/BMD-3867), and Asociación Española Contra el Cáncer. We acknowledge the NCI Outstanding Investigator Award (R35CA232105) and funding from the Ludwig Center at Harvard to FJS.

Conflicts of Interest: The authors declare no conflict of interest. Images were created with Biorender®.

References
1. Slack, F.J.; Chinnaiyan, A.M. The Role of Non-coding RNAs in Oncology. Cell 2019, 179, 1033–1055. [CrossRef]
2. Peng, W.X.; Koirala, P.; Mo, Y.Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017, 36, 5661–5667. [CrossRef]
3. Rinn, J.L.; Chang, H.Y. Genome Regulation by Long Noncoding RNAs. Annu. Rev. Biochem. 2012, 81, 145–166. [CrossRef]
4. Qian, X.; Zhao, J.; Yeung, P.Y.; Zhang, Q.C.; Kwok, C.K. Revealing IncRNA Structures and Interactions by Sequencing-Based Approaches. Trends Biochem. Sci. 2019, 44, 33–52. [CrossRef] [PubMed]
5. Anastasiadou, E.; Jacob, L.S.; Slack, F.J. Non-coding RNA networks in cancer. Nat. Rev. Cancer 2017, 18, 5–18. [CrossRef]
6. Mongelli, A.; Martelli, F.; Farsetti, A.; Gaetano, C. The dark that matters: Long noncoding RNAs as master regulators of cellular metabolism in noncommunicable diseases. Front. Physiol. 2019, 10, 369. [CrossRef] [PubMed]
7. Choi, S.W.; Kim, H.W.; Nam, J.W. The small peptide world in long noncoding RNAs. Brief. Bioinform. 2019, 20, 1853–1864. [CrossRef] [PubMed]
8. Statello, L.; Guo, C.J.; Chen, L.L.; Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 2021, 22, 96–118. [CrossRef]
9. Akhade, V.S.; Pal, D.; Kanduri, C. Advances in Experimental Medicine and Biology. In Long Noncoding RNA: Genome Organization and Mechanism of Action; Springer Nature Singapore Pte Ltd.: Singapore, 2017; Volume 1008, pp. 47–74.
10. Willingham, A.T.; Orth, A.P.; Batalov, S.; Peters, E.C.; Wen, B.G.; Aza-Blanc, P.; Hogenesch, J.B.; Schultz, P.G. A Strategy for Probing the Function of Noncoding RNAs Finds a Repressor of NFAT. Science 2005, 309, 1570–1573. [CrossRef]
11. Shamovsky, I.; Ivannikov, M.; Kandel, E.S.; Gershon, D.; Nudler, E. RNA-mediated response to heat shock in mammalian cells. Nature 2006, 440, 556–560. [CrossRef] [PubMed]
12. Tripathi, V.; Ellis, J.D.; Shen, Z.; Song, D.Y.; Pan, Q.; Watt, A.T.; Freier, S.M.; Bennett, C.F.; Sharma, A.; Bubulya, P.A.; et al. The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor Phosphorylation. Mol. Cell 2010, 39, 925–938. [CrossRef] [PubMed]
13. Bardou, F.; Ariel, F.; Simpson, C.G.; Romero-Barrios, N.; Laporte, P.; Balzerque, S.; Brown, J.W.S.; Crespi, M. Long Noncoding RNA Modulates Alternative Splicing Regulators in Arabidopsis. Dev. Cell 2014, 30, 166–176. [CrossRef] [PubMed]
14. Wang, J.; Liu, X.; Wu, H.; Ni, P.; Gu, Z.; Qiao, Y.; Chen, N.; Sun, F.; Fan, Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010, 38, 5366–5383. [CrossRef] [PubMed]
15. Jeon, Y.; Lee, J.T. YY1 Tethers Xist RNA to the Inactive X Nucleation Center. Cell 2011, 146, 119–133. [CrossRef] [PubMed]
16. Liu, X.; Li, D.; Zhang, W.; Guo, M.; Zhan, Q. Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J. 2012, 31, 4415–4427. [CrossRef]
17. Tsai, M.-C.; Manor, O.; Wan, Y.; Mosammaparast, N.; Wang, J.K.; Lan, F.; Shi, Y.; Segal, E.; Chang, H.Y. Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes. Science 2010, 329, 689–693. [CrossRef]
18. Prasanth, K.V.; Prasanth, S.G.; Xuan, Z.; Hearn, S.; Freier, S.M.; Bennett, C.F.; Zhang, M.Q.; Spector, D.L. Regulating Gene Expression through RNA Nuclear Retention. Cell 2005, 123, 249–263. [CrossRef]
19. Lee, S.; Kopp, F.; Chang, T.C.; Sataluri, A.; Chen, B.; Sivakumar, S.; Yu, H.; Xie, Y.; Mendell, J.T. Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins. Cell 2016, 164, 69–80. [CrossRef]
20. Marchese, F.P.; Grossi, E.; Marín-Béjar, O.; Bharti, S.K.; Raimondi, I.; González, J.; Martínez-Herrera, D.J.; Athie, A.; Amadoz, A.; Brosh, R.M., Jr.; et al. A Long Noncoding RNA Regulates Sister Chromatid Cohesion. Mol. Cell 2016, 63, 397–407. [CrossRef] [PubMed]
21. Lin, Y.; Schmidt, B.F.; Bruchez, M.P.; McManus, C.J. Structural analyses of NEAT1 IncRNAs suggest long-range RNA interactions that may contribute to paraseptacle architecture. *Nucleic Acids Res.* 2018, 46, 3742–3752. [CrossRef]

22. Noh, J.H.; Kim, K.M.; Abdelmohsen, K.; Yoon, J.H.; Panda, A.C.; Munk, R.; Kim, J.; Curtis, J.; Moad, C.A.; Wohler, C.M.; et al. HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the IncRNA RMRP. *Genes Dev.* 2016, 30, 1224–1239. [CrossRef]

23. Vendramini, R.; Verheyden, Y.; Ishikawa, H.; Goedert, L.; Nicolas, E.; Saraf, K.; Armaos, A.; Delli Ponti, R.; Izumikawa, K.; Mestdagh, P.; et al. SAMMSON fosters cancer cell fitness by concertedly enhancing mitochondrial and cytosolic translation. *Nat. Struct. Mol. Biol.* 2018, 25, 1035–1046. [CrossRef] [PubMed]

24. Ferré, F.; Colantoni, A.; Helmer-Citterich, M. Revealing protein-IncRNA interaction. *Brief. Bioinform.* 2016, 17, 106–116. [CrossRef] [PubMed]

25. Charles Richard, J.L.; Eichhorn, P.J.A. Platforms for Investigating LncRNA Functions. *SLAS Technol.* 2018, 23, 493–506. [CrossRef]

26. Chu, C.; Qu, K.; Zhong, F.L.; Artandi, S.E.; Chang, H.Y. Genomic Maps of Long Noncoding RNA Occupancy Reveal Principles of RNA-Chromatin Interactions. *Mol. Cell* 2011, 44, 667–678. [CrossRef]

27. Kazimierczyk, M.; Kasprzowicz, M.K.; Kasprzyk, M.E.; Wrzesinski, J. Human long noncoding RNA interactome: Detection, characterization and function. *Int. J. Mol. Sci.* 2020, 21, 1027. [CrossRef]

28. Kopp, F.; Mendell, J.T. Functional Classification and Experimental Dissection of Long Noncoding RNAs. *Cell* 2015, 161, 3965–3981. [CrossRef] [PubMed]

29. Mattick, J.S.; Rinn, J.L. Discovery and annotation of long noncoding RNAs. *Nat. Struct. Mol. Biol.* 2015, 22, 5–7. [CrossRef] [PubMed]

30. Marques-Rocha, J.L.; Samblas, M.; Milagro, F.I.; Bressan, J.; Martínez, J.A.; Martí, A. Noncoding RNAs, cytokines, and inflammation-related diseases. *FASEB J.* 2015, 29, 3595–3611. [CrossRef] [PubMed]

31. Matsui, M.; Corey, D.R. Non-coding RNAs as drug targets. *Nat. Rev. Drug Discov.* 2011, 10, 91–107. [CrossRef]

32. Ding, Q.; Li, Y.; Wang, Z.; Zhou, S.; Sun, H.; Yu, G. The Evolution and Expression Pattern of Human Overlapping IncRNA and Protein-coding Gene Pairs. *Sci. Rep.* 2017, 7, 1–12. [CrossRef]

33. Katayama, S.; Tomaru, Y.; Kasukawa, T.; Waki, K.; Nakanishi, M.; Nakamura, M.; Nishida, H.; Yap, C.C.; Suzuki, M.; Kawai, J.; et al. Molecular biology: Antisense transcription in the mammalian transcriptome. *Science* 2005, 309, 1564–1566. [CrossRef]

34. Hua, J.T.; Ahmed, M.; Guo, H.; Zhang, Y.; Chen, S.; Soares, F.; Lu, J.; Zhou, S.; Wang, M.; Li, H.; et al. Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through IncRNA PCAT19. *Cell* 2018, 174, 564–575.e18. [CrossRef]

35. Mal, L.; Sun, X.; Kuai, W.; Hu, J.; Yuan, Y.; Feng, W.; Lu, X. LncRNA SOX2 overlapping transcript acts as a miRNA sponge to promote the proliferation and invasion of Ewing’s sarcoma. *Am. J. Transl. Res.* 2019, 11, 3841–3849. [CrossRef]

36. Wang, J.; Su, Z.; Lu, S.; Fu, W.; Liu, Z.; Jiang, X.; Tai, S. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. *Clin. Chim. Acta* 2018, 485, 229–233. [CrossRef] [PubMed]

37. Ulitsky, I.; Bartel, D.P. XlincRNAs: Genomics, evolution, and mechanisms. *Cell* 2013, 154, 26. [CrossRef] [PubMed]

38. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. *Cell* 2013, 144, 646–674. [CrossRef] [PubMed]

39. Bhan, A.; Mandal, S.S. Long noncoding RNAs: Emerging stars in gene regulation, epigenetics and human disease. *ChemMedChem* 2014, 9, 1932–1956. [CrossRef] [PubMed]

40. Schmitt, A.M.; Chang, H.Y. Long Noncoding RNAs in Cancer Pathways. *Cancer Cell* 2016, 29, 452–463. [CrossRef]

41. Renganathan, A.; Felley-Bosco, E. Long noncoding RNAs in cancer and therapeutic potential. *Adv. Exp. Med. Biol.* 2017, 1008, 199–222. [CrossRef] [PubMed]

42. Huarque, M. The emerging role of IncRNAs in cancer. *Nat. Med.* 2015, 21, 1253–1261. [CrossRef]

43. Guzel, E. Tumor Suppressor and Oncogenic Role of Long Non-Coding RNAs in Cancer. *North. Clin. Istanbul* 2019, 7, 81–86. [CrossRef] [PubMed]

44. Li, W.; Chen, Y.; Nie, X. Regulatory Mechanisms of IncRNAs and Their Target Gene Signaling Pathways in Laryngeal Squamous Cell Carcinoma. *Front. Pharmacol.* 2020, 11, 1140. [CrossRef] [PubMed]

45. Dahl, M.; Kristensen, L.S.; Grembek, K. Long non-coding RNAs guide the fine-tuning of gene regulation in B-cell development and malignancy. *Int. J. Mol. Sci.* 2018, 19, 2475. [CrossRef] [PubMed]

46. Shin, T.J.; Lee, K.H.; Cho, J.Y. Epigenetic mechanisms of Incrnas binding to protein in carcinogenesis. *Cancers* 2020, 12, 2925. [CrossRef]

47. Sun, Y.; Ma, L. New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis. *Cancers* 2019, 11, 216. [CrossRef]

48. Bhan, A.; Soleimani, M.; Mandal, S.S. Long noncoding RNA and cancer: A new paradigm. *Cancer Res.* 2017, 77, 3965–3981. [CrossRef]

49. Carvajal, R.D.; Schwartz, G.K.; Tezel, T.; Marr, B.; Francis, J.H.; Nathan, P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. *Br. J. Ophthalmon.* 2017, 101, 38–44. [CrossRef] [PubMed]

50. Kaliki, S.; Shields, C.L. Uveal melanoma: Relatively rare but deadly cancer. *Eye* 2017, 31, 241–257. [CrossRef] [PubMed]

51. Croce, M.; Ferrini, S.; Pfefrer, U.; Gangemi, R. Targeted therapy of uveal melanoma: Recent failures and new perspectives. *Cancers* 2019, 11, 846. [CrossRef]

52. Louie, B.H.; Kurzrock, R. BAP1: Not just a BRCA1-associated protein. *Cancer Treat. Rev.* 2020, 90. [CrossRef]

53. Li, Y.; Jia, R.; Ge, S. Role of epigenetics in uveal melanoma. *Int. J. Biol. Sci.* 2017, 13, 426–433. [CrossRef]
Cancers 2019, 11, 694. [CrossRef]  

Rantala, E.S.; Hernberg, M.; Kivelä, T.T. Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis. *Melanoma Res.* 2019, 29, 561–568. [CrossRef]  

Souto, E.B.; Zielinska, A.; Luis, M.; Carbone, C.; Martins-Gomes, C.; Souto, S.B.; Silva, A.M. Uveal melanoma: Physiopathology and new in situ-specific therapies. *Cancer Chemother. Pharmacol.* 2019, 84, 15–32. [CrossRef]  

Buder, K.; Gesierich, A.; Gelbrich, G.; Goebeler, M. Systemic treatment of metastatic uveal melanoma: Review of literature and future perspectives. *Cancer Med.* 2013, 2, 674–686. [CrossRef]  

Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; et al. Uveal melanoma. *Nat. Rev. Dis. Prim.* 2020, 6. [CrossRef]  

Zhang, L.; Dong, Y.; Wang, Y.; Gao, J.; Lv, J.; Sun, J.; Li, M.; Wang, M.; Zhao, Z.; Wang, J.; et al. Long non-coding RNAs in ocular diseases: New and potential therapeutic targets. FEBs J. 2019, 286, 2261–2272. [CrossRef]  

Pan, H.; Ni, H.; Zhang, L.L.; Xing, Y.; Fan, J.; Li, P.; Li, T.; Jia, R.; Ge, S.; Zhang, H.; et al. 2PRK7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma. *Tumor Biol.* 2016, 37, 13533–13543. [CrossRef] [PubMed]  

Sun, L.; Sun; P.; Zhou, Q.Y.; Gao, X.; Han, Q. Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140. *Am. J. Ophthalmol.* 2016, 8, 3939–3946. [PubMed]  

Wu, S.; Chen, H.; Zuo, L.; Jiang, H.; Yan, H. Suppression of long noncoding RNA MALAT1 inhibits the development of uveal melanoma via microRNA-608-mediated inhibition of HOXC4. *Am. J. Physiol. Physiol.* 2020, 318, C903–C912. [CrossRef] [PubMed]  

Huang, X.M.; Shi, S.S.; Jian, T.M.; Tang, D.R.; Wu, T.; Sun, F.Y. LncRNA PVT1 knockdown affects proliferation and apoptosis of uveal melanoma cells by inhibiting EZH2. *Eur. Rev. Med. Pharmacol. Sci.* 2019, 23, 2880–2887. [CrossRef]  

Wu, S.; Chen, H.; Han, N.; Zhang, C.; Yan, H. Long noncoding RNA PVT1 silencing prevents the development of uveal melanoma by impairing microRNA-17-3p–dependent MDM2 upregulation. *Investig. Ophthalmo. Vis. Sci.* 2019, 60, 4904–4914. [CrossRef] [PubMed]  

Lu, L.; Yu, X.; Zhang, L.; Ding, X.; Pan, H.; Wen, X.; Xu, S.; Xing, Y.; Fan, J.; Ge, S.; et al. The long non-coding RNA RHPN1-AS1 promotes uveal melanoma progression. *Int. J. Mol. Sci.* 2017, 18, 226. [CrossRef]  

Lu, Q.; Zhao, N.; Zha, G.; Wang, H.; Tong, Q.; Xin, S. LncRNA HOXA11-AS Exerts Oncogenic Functions by Repressing p21 and miR-124 in Uveal Melanoma. *DNA Cell Biol.* 2017, 36, 837–844. [CrossRef] [PubMed]  

Zheng, X.; Tang, H.; Zhao, X.; Sun, Y.; Jiang, Y.; Liu, Y. Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p. *PLoS ONE* 2017, 12, e0184746. [CrossRef] [PubMed]  

Barbagallo, C.; Calitabiano, R.; Broggi, G.; Russo, A.; Puzzo, L.; Avitabile, T.; Longo, A.; Reibaldi, M.; Barbagallo, D.; Di Pietro, C.; et al. LncRNA LINC00518 Acts as an Oncogene in Uveal Melanoma by Regulating an RNA-Based Network. *Cancers* 2020, 12, 3867. [CrossRef]  

Qi, Y.; Yao, R.; Zhang, W.; Cui, Q.; Zhang, F. Knockdown of Long Non-Coding RNA LOC100132707 Inhibits the Migration of Uveal Melanoma Cells via Silencing JAK2. *Onco. Targets. Ther.* 2020, 13, 12955–12964. [CrossRef] [PubMed]  

Ding, X.; Wang, X.; Lin, M.; Xing, Y.; Ge, S.; Jia, R.; Zhang, H.; Fan, X.; Li, J. PAUPAR lncRNA suppresses tumorigenesis by H3K4 demethylation in uveal melanoma. *FEBS Lett.* 2016, 1729–1738. [CrossRef]  

Cheng, G.; He, J.; Zhang, L.; Ge, S.; Zhang, H.; Fan, X. HIC1 modulates uveal melanoma progression by activating lncRNA numb. *Tumor Biol.* 2016, 37, 12779–12789. [CrossRef]  

Xing, Y.; Wen, X.; Ding, X.; Fan, J.; Chai, P.; Jia, R.; Ge, S.; Qian, G.; Zhang, H.; Fan, X. CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant Invasive Cascade in Malignant Uveal Melanoma. *Mol. Ther.* 2017, 25, 1209–1221. [CrossRef]  

Li, P.; He, J.; Yang, Z.; Ge, S.; Zhang, H.; Zhong, Q.; Fan, X. ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression. *Autophagy* 2019, 3, 1–14. [CrossRef]  

Wu, X.; Yuan, Y.; Ma, R.; Xu, B.; Zhang, R. LncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines. * Oncol. Lett. 2020, 19, 1505–1515. [CrossRef]  

Qi, Y.; Cui, Q.; Zhang, W.; Yao, R.; Xu, D.; Zhang, F. Long Non-Coding RNA GAS5 Targeting microRNA-21 to Suppress the Invasion and Epithelial–Mesenchymal Transition of Uveal Melanoma. *Cancer Manag. Res.* 2020, 12, 12259. [CrossRef] [PubMed]  

Mishra, S.; Maurya, S.K.; Srivastava, K.; Shukla, S.; Mishra, R. Pax6 influences expression patterns of genes involved in neuro-degeneration. *Ann. Neurosci.* 2015, 22, 226–231. [CrossRef]  

Singer, R.A.; Arnes, L.; Cui, Y.; Wang, J.; Gao, Y.; Guney, M.A.; Burnum-Johnson, K.E.; Rabdan, R.; Ansong, C.; Orr, G.; et al. The Long Noncoding RNA Paupar Modulates PX6 Regulatory Activities to Promote Alpha Cell Development and Function. *Cell Metab.* 2019, 30, 1091–1106.e8. [CrossRef]
81. Vance, K.W.; Sansom, S.N.; Lee, S.; Chalei, V.; Kong, L.; Cooper, S.E.; Oliver, P.L.; Ponting, C.P. The long non-coding RNA paupar regulates the expression of both local and distal genes. EMBO J. 2014, 33, 296–311. [CrossRef]

82. Liu, H.; Lei, C.; Long, K.; Yang, X.; Zhu, Z.; Zhang, L.; Liu, J. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol. Rep. 2015, 34, 295–301. [CrossRef] [PubMed]

83. Rood, B.R.; Leprince, D. Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics. Expert Opin. Ther. Targets 2013, 17, 811–827. [CrossRef] [PubMed]

84. Liu, H.; Lei, C.; Long, K.; Yang, X.; Zhu, Z.; Zhang, L.; Liu, J. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells. [CrossRef] [PubMed]

85. Lessard, L.; Liu, M.; Marzese, D.M.; Wang, H.; Chong, K.; Kawas, N.; Donovan, N.C.; Kiyohara, E.; Hsu, S.; Nelson, N.; et al. The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. J. Invest. Dermatol. 2015, 135, 2464–2474. [CrossRef] [PubMed]

86. Liu, X.; Song, Y.; Tang, L.; Sun, D.-H.; Ji, D.-G. LncRNA SNHG7 promotes development of breast cancer by regulating miRNA-186. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 7788–7797. [CrossRef] [PubMed]

87. Zhong, X.; Long, Z.; Wu, S.; Xiao, M.; Hu, W. LncRNA-SNHG7 regulates proliferation, apoptosis and invasion of bladder cancer cells. J. BU ON. 2018, 23, 776–781.

88. Wang, M.W.; Liu, J.; Liu, Q.; Xu, Q.H.; Li, T.F.; Jin, S.; Xia, T.S. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 4631–4622.

89. Li, Y.; Zeng, C.; Hu, J.; Pan, Y.; Shan, Y.; Liu, B.; Jia, L. Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate P13K/Akt/mTOR pathway in colorectal cancer progression. J. Hematol. Oncol. 2018, 11, 89. [CrossRef]

90. Cheng, D.; Fan, J.; Ma, Y.; Zhou, Y.; Qin, K.; Shi, M.; Yang, J. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Cell Biosci. 2019, 9, 1–11. [CrossRef]

91. Pei, Y.; He, Y.; Hu, L.; Zhou, B.; Xu, H.; Liu, X. The cross-talk between LncRNA-SNHG7/microRNA-181/cbx7 modulates malignant character in lung adenocarcinoma. Am. J. Pathol. 2020. [CrossRef]

92. Tang, R.; Jiang, M.; Liang, D.; Xia, Y.; Yang, D.; Chen, G. Long noncoding RNA MALAT-1 can predict poor prognosis: A meta-analysis. Med. Sci. Monit. 2016, 22, 302–309. [CrossRef]

93. Tripathi, V.; Zhou, X.; Chakraborty, A.; Giri, S.; Freier, S.M.; Wu, X.; Zhang, Y.; Gorospe, M.; Prasanth, S.G.; Lal, A.; et al. Long Noncoding RNA MALAT1 Controls Cell Cycle Progression by Regulating the Expression of Oncogenic Transcription Factor B-MYB. PLoS Genet. 2013, 9. [CrossRef] [PubMed]

94. Xu, H.; Gong, J.; Liu, H. High expression of lncRNA PVT1 independently predicts poor overall survival in patients with primary uveal melanoma. PLoS ONE 2017, 12, e0189675. [CrossRef] [PubMed]

95. Huang, T.; Liu, H.W.; Chen, J.Q.; Wang, S.H.; Hao, L.Q.; Liu, M.; Wang, B. The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed. Pharmacother. 2017, 88, 302–308. [CrossRef]

96. Wang, B.J.; Ding, H.W.; Ma, G.A. Long noncoding RNA PVT1 promotes melanoma progression via endogenous sponging miR-26b. Oncol. Res. 2018, 26, 675–681. [CrossRef]

97. Zhao, L.; Kong, H.; Sun, H.; Chen, Z.; Chen, B.; Zhou, M. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through the miR sponge to regulate miR-448. J. Cell. Physiol. 2018, 233, 4044–4055. [CrossRef]

98. Li, P.D.; Hu, J.L.; Ma, C.; Ma, H.; Yao, J.; Chen, L.L.; Chen, J.; Cheng, T.T.; Yang, K.Y.; Wu, G.; et al. Upregulation of the long non-coding RNA PVT1 promotes esophageal squamous cell carcinoma progression by acting as a molecular sponge of miR-203 and LASP1. Oncotarget 2017, 8, 34164–34176. [CrossRef]

99. Duan, H.; Li, X.; Chen, Y.; Wang, Y.; Li, Z. LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p/FG22 axis. Life Sci. 2019, 239, 116856. [CrossRef] [PubMed]

100. Cui, P.; Su, J.; Li, Q.; Xu, G.; Zhu, N. LncRNA RHPN1-AS1 promoting epithelial-mesenchymal transition. Int. J. Clin. Exp. Pathol. 2019, 12, 3782–3790. [PubMed]

101. Jiang, M.; Liu, H.; Yang, Q.; He, Y.; Yan, Y.; Li, N.; You, W. Long noncoding RNA RHPN1-AS1, induced by KDM5B, is involved in melanoma cells through the activation of Notch signaling. EMBO J. 2014, 33, 7911–7921. [CrossRef] [PubMed]

102. Fan, Y.; Yan, T.; Chai, Y.; Jiang, Y.; Zhu, X. Long noncoding RNA HOTTP as an independent prognostic marker in cancer. Clin. Chim. Acta 2018, 482, 224–230. [CrossRef]

103. Li, L.; Wang, Y.; Song, G.; Zhang, X.; Gao, S.; Liu, H. HOX cluster-embedded antisense long non-coding RNAs in lung cancer. Cancer Lett. 2019, 450, 14–21. [CrossRef]

104. Lu, C.-W.; Zhou, D.-D.; Xie, T.; Hao, G.L.; Pant, O.P.; Lu, C.B.; Liu, X.F. HOXA11 antisense long noncoding RNA (HOXA11-AS): A promising IncRNA in human cancers. Cancer Med. 2018, 7, 3792–3799. [CrossRef] [PubMed]

105. Su, J.C.; Hu, X.F. Long non-coding RNA HOXA11-AS promotes cell proliferation and metastasis in human breast cancer. Mol. Med. Rep. 2017, 16, 4887–4894. [CrossRef] [PubMed]

106. Li, Z.; Wang, Y. Long non-coding RNA FTH1P3 promotes the metastasis and aggressiveness of non-small cell lung carcinoma by inducing epithelial-mesenchymal transition. Int. J. Clin. Exp. Pathol. 2019, 12, 3782–3790. [PubMed]
108. Zhang, Y.; Ying, L.I.; Wang, J.; Lei, P. Long non-coding RNA ferritin heavy polypeptide 3 pseudogene 3 controls glioma cell proliferation and apoptosis via regulation of the microRNA-224-5p/tumor protein D52 axis. *Mol. Med. Rep.* 2018, 18, 4239–4246. [CrossRef]

109. Yang, L.; Sun, K.; Chu, J.; Qu, Y.; Zhao, X.; Yin, H.; Ming, L.; Wan, J.; He, F. Long non-coding RNA FTH1P3 regulated metastasis and invasion of esophageal squamous cell carcinoma through SP1/NF-κB pathway. *Biomed. Pharmacother.* 2018, 106, 1570–1577. [CrossRef]

110. Wang, R.; Zhang, T.; Yang, Z.; Jiang, C.; Seng, J. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABC1B1. *J. Cell. Mol. Med.* 2018, 22, 4068–4075. [CrossRef]

111. Yang, L.; Sun, K.; Chu, J.; Qu, Y.; Zhao, X.; Yin, H.; Ming, L.; Wan, J.; He, F. Long non-coding RNA FTH1P3 regulated metastasis and invasion of esophageal squamous cell carcinoma through SP1/NF-κB pathway. *Biomed. Pharmacother.* 2018, 106, 1570–1577. [CrossRef]

112. Lavorgna, G.; Vago, R.; Sarmini, M.; Montorsi, F.; Salonia, A.; Bellone, M. Long non-coding RNAs as novel therapeutic targets in cancer. *Pharmacol. Res.* 2016, 110, 131–138. [CrossRef] [PubMed]

113. Chandra Gupta, S.; Nandan Tripathi, Y. Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. *Int. J. Cancer*. 2017, 140, 1955–1967. [CrossRef] [PubMed]

114. Wang, H.; Huo, X.; Yang, X.; He, J.; Cheng, L.; Wang, N.; Deng, X.; Jin, H.; Wang, N.; Wang, C.; et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. *Mol. Cancer* 2017, 16, 136. [CrossRef] [PubMed]

115. Zhang, Z.; Wang, S.; Yang, F.; Meng, Z.; Liu, Y. LncRNA ROR1-AS1 high expression and its prognostic significance in liver cancer. * Oncol. Rep.* 2020, 43, 55–74. [CrossRef] [PubMed]

116. Wang, H.; Huo, X.; Yang, X.; He, J.; Cheng, L.; Wang, N.; Deng, X.; Jin, H.; Wang, N.; Wang, C.; et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. *Mol. Cancer* 2017, 16, 136. [CrossRef] [PubMed]

117. Manzano, M.; Vallet-Regí, M. Mesoporous silica nanoparticles in nanomedicine applications. *J. Mater. Sci. Mater. Med.* 2018, 29, 65. [CrossRef]

118. Steinmetz, N.F. Viral Nanoparticles in Drug Delivery and Imaging. *Mol. Pharm.* 2013, 10, 1–2. [CrossRef]

119. Ren, Y.; Li, R.Q.; Cai, Y.R.; Xia, T.; Yang, M.; Xu, F.J. Effective Codelivery of lncRNA and pDNA by Pullulan-Based Nanovecto For Promising Therapy of Hepatocellular Carcinoma. *Adv. Funct. Mater.* 2016, 26, 7314–7325. [CrossRef]

120. Vaidya, A.M.; Marta, B.F.; et al. Blood Biomarkers of Uveal Melanoma: Current Perspectives. *Clin. Ophthalmol.* 2019, 30, 907–919. [CrossRef] [PubMed]

121. Manzano, M.; Vallet-Regí, M. Mesoporous silica nanoparticles in nanomedicine applications. *J. Mater. Sci. Mater. Med.* 2018, 29, 65. [CrossRef]

122. Steinmetz, N.F. Viral Nanoparticles in Drug Delivery and Imaging. *Mol. Pharm.* 2013, 10, 1–2. [CrossRef]

123. Steinmetz, N.F. Viral Nanoparticles in Drug Delivery and Imaging. *Mol. Pharm.* 2013, 10, 1–2. [CrossRef]

124. Gou, Y.; Miao, D.; Zhou, M.; Wang, L.; Zhou, H.; Su, G. Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics. *Int. J. Mol. Sci.* 2018, 19, 246. [CrossRef] [PubMed]

125. Pattni, B.S.; Chupin, V.V.; Torchilin, V.P. New Developments in Liposomal Drug Delivery. *Adv. Drug Deliv. Rev.* 2013, 65, 331–345. [CrossRef]

126. Núñez, C.; Estévez, S.V.; del Pilar Chantada, M. Inorganic nanoparticles in diagnosis and treatment of breast cancer. *JBC J. Biol. Inorg. Chem.* 2018, 23, 331–345. [CrossRef] [PubMed]

127. Mishra, D.K.; Sandilya, R.; Mishra, P.K. Lipid based nanocarriers: A translational perspective. *Nanomed. Nanotechnol. Biol. Med.* 2018, 14, 2023–2050. [CrossRef] [PubMed]

128. Zhang, Y.; Ying, L.I.; Wang, J.; Lei, P. Long non-coding RNA ferritin heavy polypeptide 3 pseudogene 3 controls glioma cell proliferation and apoptosis via regulation of the microRNA-224-5p/tumor protein D52 axis. *Mol. Med. Rep.* 2018, 18, 4239–4246. [CrossRef]

129. Vaidya, A.M.; Marta, B.F.; et al. Blood Biomarkers of Uveal Melanoma: Current Perspectives. *Clin. Ophthalmol.* 2019, 30, 907–919. [CrossRef] [PubMed]

130. Zhang, Z.; Wang, S.; Yang, F.; Meng, Z.; Liu, Y. LncRNA ROR1-AS1 high expression and its prognostic significance in liver cancer. *Oncol. Rep.* 2020, 43, 55–74. [CrossRef] [PubMed]

131. Zhang, Z.; Wang, S.; Yang, F.; Meng, Z.; Liu, Y. LncRNA ROR1-AS1 high expression and its prognostic significance in liver cancer. *Oncol. Rep.* 2020, 43, 55–74. [CrossRef] [PubMed]

132. Wang, H.; Huo, X.; Yang, X.; He, J.; Cheng, L.; Wang, N.; Deng, X.; Jin, H.; Wang, N.; Wang, C.; et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. *Mol. Cancer* 2017, 16, 136. [CrossRef] [PubMed]

133. Wang, H.; Huo, X.; Yang, X.; He, J.; Cheng, L.; Wang, N.; Deng, X.; Jin, H.; Wang, N.; Wang, C.; et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. *Mol. Cancer* 2017, 16, 136. [CrossRef] [PubMed]

134. Jiang, N.; Pan, J.; Fang, S.; Zhou, C.; Han, Y.; Chen, J.; Meng, X.; Jin, X.; Gong, Z. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer. *Clin. Chim. Acta*, 2019, 495, 331–337. [CrossRef] [PubMed]

135. Rodriguez, M.F.B.; Marta, B.F.; Baimeiro, N.L.; Santiago-Varela, M.; Silva-Rodriguez, P.; Blanco-Teijeiro, M.J.; Perez, M.P.; Ces, A.P.; Bande Rodriguez, M.F.; Fernandez Marta, B.; et al. Blood Biomarkers of Uveal Melanoma: Current Perspectives. *Clin. Ophthalmol.* 2020, 14, 157–169. [CrossRef] [PubMed]
136. Barak, V.; Frenkel, S.; Kalickman, I.; Maniotis, A.J.; Folberg, R.; Pe’er, J. Serum markers to detect metastatic uveal melanoma. *Anticancer Res.* **2007**, *27*, 1897–1900.

137. Anfossi, S.; Babayan, A.; Pantel, K.; Calin, G.A. Clinical utility of circulating non-coding RNAs — an update. *Nat. Rev. Clin. Oncol.* **2018**, *15*, 541–563. [CrossRef]

138. Wang, M.; Gu, H.; Qian, H.; Zhu, W.; Zhao, C.; Zhang, X.; Tao, Y.; Zhang, L.; Xu, W. MiR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. *Eur. J. Cancer* **2013**, *49*, 2010–2021. [CrossRef]

139. HOXC4 Homeobox C4 [*Homo sapiens* (Human)]-Gene-NCBI. Available online: https://www.ncbi.nlm.nih.gov/gene/3221 (accessed on 26 October 2020).

140. AKT2 AKT Serine/Threonine Kinase 2 [*Homo sapiens* (Human)]-Gene-NCBI. Available online: https://www.ncbi.nlm.nih.gov/gene/208 (accessed on 26 October 2020).

141. Tinzl, M.; Marberger, M.; Horvath, S.; Chypre, C. DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. *Eur. Urol.* **2004**, *46*, 182–187. [CrossRef]

142. Barbagallo, C.; Di Maria, A.; Alecci, A.; Barbagallo, D.; Alaimo, S.; Colarossi, L.; Ferro, A.; Di Pietro, C.; Purrello, M.; Pulvirenti, A.; et al. VECTOR: An Integrated Correlation Network Database for the Identification of CeRNA Axes in Uveal Melanoma. *Genes* **2021**, *12*, 1004. [CrossRef] [PubMed]

143. Shohet, J.; Kim, E. Targeted molecular therapy for neuroblastoma: The ARF/MDM2/p53 Axis. *J. Natl. Cancer Inst.* **2009**, *101*, 1527–1529. [CrossRef]

144. Amodio, N.; Raimondi, L.; Juli, G.; Stamato, M.A.; Caracciolo, D.; Tagliaferri, P.; Tassone, P. MALAT1: A druggable long non-coding RNA for targeted anti-cancer approaches. *J. Hematol. Oncol.* **2018**, *11*, 1–19. [CrossRef] [PubMed]

145. Duan, R.; Du, W.; Guo, W. EZH2: A novel target for cancer treatment. *J. Hematol. Oncol.* **2020**, *13*. [CrossRef] [PubMed]

146. Peixoto, P.; Grandvallet, C.; Feugeas, J.P.; Guittaut, M.; Hervouet, E. Epigenetic Control of Autophagy in Cancer Cells: A Key Process for Cancer-Related Phenotypes. *Cells* **2019**, *8*, 1656. [CrossRef] [PubMed]